Although it was my first time investing in "Biotech" company, I thought I had spent a fair amount of time doing due-diligence on ISCO. The company along with its subsidiaries has been generating very stable revenues even in the growing pattern, insider ownership is very high, and also the stock price is significantly undervalued comparing to many other biotech companies which don't even have any revenues at all. I just do not understand why the stock price is constantly pulling back. Is there anything that we don't know? Please advise and share if anyone knows. I very strongly long ISCO, and have no doubts that it will eventually become one of those, so-called, multi-baggers.
UK Patent Office refuses patent applications to parthenogenetically-derived human embryonic stem cells. For this reason their whole value is basically in question. Green Peace could challenge in the US if the FDA ok's ISCO for clinical trials. A slippery slope. This is why they are 0.15.
Biotime's process of isolating, purifying and reprogramming specific hESC derived progenitors is much more likely to proceed without patent issues, this is why their stock is much higher.
I personally believe the FDA is in the pocket of big pharma. Big pharma wants to keep the maintenance medicine and/or procedures since they are big ticket items. Anything that hints at curing a disease scares the H out of them. As a consequence, the FDA puts up as many roadblocks as they can.
One thing you must realize is the biotech sector has taken a beating over the last few weeks after the big guys said it was "overvalued". I have 4 that are quality stocks and they have had the stuffing beat out of them. Also the R and D side of the company has been slow to meet objectives and should be alot farther along than they are. I'm sure there are other factors more learned folks could address. GLTY